SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

07 Feb 2025 Evaluate
The revenue for the December 2024 quarter is pegged at Rs. 22868.30 millions, about 13.84% up against Rs. 20088.80 millions recorded during the year-ago period.The company has announced a 48.52% increase in its profits to Rs . 6762.30  millions for the  quarter ended December 2024 compared to Rs. 4553.20 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 8270.10 millions from 5880.00 millions in the quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 22868.30 20088.80 13.84 76589.00 68966.40 11.05 97477.20 90545.50 7.66
Other Income 1691.80 956.60 76.86 3954.70 2222.00 77.98 3059.90 2662.90 14.91
PBIDT 8270.10 5880.00 40.65 24015.70 17028.90 41.03 22711.20 16432.40 38.21
Interest 210.00 206.60 1.65 600.10 607.80 -1.27 819.10 864.00 -5.20
PBDT 8060.10 5160.30 56.19 23415.60 15908.00 47.19 21253.80 15568.40 36.52
Depreciation 676.10 568.30 18.97 1945.50 1739.60 11.84 2443.50 2298.50 6.31
PBT 7384.00 4592.00 60.80 21470.10 14168.40 51.54 18810.30 13269.90 41.75
TAX 621.70 38.80 1502.32 1899.50 435.70 335.97 1338.80 1925.20 -30.46
Deferred Tax -577.10 -603.10 -4.31 -1735.10 -1860.30 -6.73 -1994.00 -350.00 469.71
PAT 6762.30 4553.20 48.52 19570.60 13732.70 42.51 17471.50 11344.70 54.01
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 36.16 29.27 23.55 31.36 24.69 26.99 23.30 18.15 28.38

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×